Condition or disease | Intervention/treatment | Phase |
---|---|---|
Diffuse Large B-cell Lymphoma | Biological: CTA101 | Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 9 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Phase I Clinical Trial of CTA101 UCART Cells Injection in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma |
Estimated Study Start Date : | December 1, 2019 |
Estimated Primary Completion Date : | August 31, 2022 |
Estimated Study Completion Date : | December 31, 2022 |
Arm | Intervention/treatment |
---|---|
Experimental: CTA101 |
Biological: CTA101
Universal CD19-directed CAR-T cells by a single infusion intravenously will be given in escalating doses. Subjects will been distributed into low dose (0.2×10^6), medium dose (2×10^6), and high dose (3×10^6).
|
Ages Eligible for Study: | 18 Years to 70 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Relapsed or refractory DLBCL (meeting one of the following conditions):
Exclusion Criteria:
History of other primary cancer, except for the following conditions:
Contact: Jianyong Li, Ph.D. | 025-83718836 | lijianyonglm@126.com |
China, Jiangsu | |
the First Affiliated Hospital of Nanjing Medical University | |
Nanjing, Jiangsu, China, 210000 |
Tracking Information | |||||
---|---|---|---|---|---|
First Submitted Date ICMJE | July 17, 2019 | ||||
First Posted Date ICMJE | July 19, 2019 | ||||
Last Update Posted Date | October 31, 2019 | ||||
Estimated Study Start Date ICMJE | December 1, 2019 | ||||
Estimated Primary Completion Date | August 31, 2022 (Final data collection date for primary outcome measure) | ||||
Current Primary Outcome Measures ICMJE |
Dose-limiting toxicity(DLT) [ Time Frame: Baseline up to 35 days after T cell infusion ] Adverse events assessed according to NCI-CTCAE v4.03 criteria
|
||||
Original Primary Outcome Measures ICMJE | Same as current | ||||
Change History | |||||
Current Secondary Outcome Measures ICMJE |
|
||||
Original Secondary Outcome Measures ICMJE | Same as current | ||||
Current Other Pre-specified Outcome Measures | Not Provided | ||||
Original Other Pre-specified Outcome Measures | Not Provided | ||||
Descriptive Information | |||||
Brief Title ICMJE | CTA101 in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma | ||||
Official Title ICMJE | A Phase I Clinical Trial of CTA101 UCART Cells Injection in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma | ||||
Brief Summary | This is a single-center, non-randomized and dose-escalation study to evaluate the safety and efficacy of CTA101 in relapsed or refractory diffuse large B-cell lymphoma patients. | ||||
Detailed Description | Not Provided | ||||
Study Type ICMJE | Interventional | ||||
Study Phase ICMJE | Phase 1 | ||||
Study Design ICMJE | Allocation: N/A Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment |
||||
Condition ICMJE | Diffuse Large B-cell Lymphoma | ||||
Intervention ICMJE | Biological: CTA101
Universal CD19-directed CAR-T cells by a single infusion intravenously will be given in escalating doses. Subjects will been distributed into low dose (0.2×10^6), medium dose (2×10^6), and high dose (3×10^6).
|
||||
Study Arms ICMJE | Experimental: CTA101
Intervention: Biological: CTA101
|
||||
Publications * | Not Provided | ||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||
Recruitment Information | |||||
Recruitment Status ICMJE | Not yet recruiting | ||||
Estimated Enrollment ICMJE |
9 | ||||
Original Estimated Enrollment ICMJE | Same as current | ||||
Estimated Study Completion Date ICMJE | December 31, 2022 | ||||
Estimated Primary Completion Date | August 31, 2022 (Final data collection date for primary outcome measure) | ||||
Eligibility Criteria ICMJE |
Inclusion Criteria:
Exclusion Criteria:
|
||||
Sex/Gender ICMJE |
|
||||
Ages ICMJE | 18 Years to 70 Years (Adult, Older Adult) | ||||
Accepts Healthy Volunteers ICMJE | Yes | ||||
Contacts ICMJE |
|
||||
Listed Location Countries ICMJE | China | ||||
Removed Location Countries | |||||
Administrative Information | |||||
NCT Number ICMJE | NCT04026100 | ||||
Other Study ID Numbers ICMJE | JSPH-CTA101 | ||||
Has Data Monitoring Committee | Not Provided | ||||
U.S. FDA-regulated Product |
|
||||
IPD Sharing Statement ICMJE | Not Provided | ||||
Responsible Party | The First Affiliated Hospital with Nanjing Medical University | ||||
Study Sponsor ICMJE | The First Affiliated Hospital with Nanjing Medical University | ||||
Collaborators ICMJE | Nanjing Bioheng Biotech Co., Ltd. | ||||
Investigators ICMJE | Not Provided | ||||
PRS Account | The First Affiliated Hospital with Nanjing Medical University | ||||
Verification Date | October 2019 | ||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |